AMRX

SEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 6

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,634

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

SEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 5

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,788

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 4

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,530

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

SEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 3

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,427

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 2

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,733

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

SEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 191,678

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · derivative · entry 14

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 366,972 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.

F4 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.

F4 · derivative.expiration_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.

SEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · derivative · entry 13

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,634

Underlying: Class A Common Stock · 23,544 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F8 · derivative.exercise_date: On March 3, 2025, the reporting person was granted 94,178 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

F8 · derivative.expiration_date: On March 3, 2025, the reporting person was granted 94,178 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

SEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · derivative · entry 12

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,872

Underlying: Class A Common Stock · 45,871 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F7 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 183,486 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

F7 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 183,486 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

SEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · derivative · entry 11

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 36,232 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F6 · derivative.exercise_date: On March 3, 2022, the reporting person was granted 144,928 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

F6 · derivative.expiration_date: On March 3, 2022, the reporting person was granted 144,928 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

SEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 8

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 381,889

F5 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units.

SEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 7

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 565,742

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.

SEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 6

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 198,770

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

SEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 5

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,566

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 4

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,022

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

SEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 3

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,004

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 2

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,133

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

SEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 1

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,635

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-26-013900 · wk-form4_1772573379.xml · derivative · entry 2

Patel Chintu · CIK 0001737428 · Director · Co-CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 354,031

Underlying: Class A Common Stock · 354,031 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 354,031 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

F4 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 354,031 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

SEC source: 0001628280-26-013900 · wk-form4_1772573379.xml · derivative · entry 1

Patel Chintu · CIK 0001737428 · Director · Co-CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,632

Underlying: Class A Common Stock · 190,632 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

SEC source: 0001628280-26-013893 · wk-form4_1772573340.xml · derivative · entry 2

Patel Chirag K. · CIK 0001738701 · Director · President & Co-CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 354,031

Underlying: Class A Common Stock · 354,031 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 354,031 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

F4 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 354,031 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

SEC source: 0001628280-26-013893 · wk-form4_1772573340.xml · derivative · entry 1

Patel Chirag K. · CIK 0001738701 · Director · President & Co-CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,632

Underlying: Class A Common Stock · 190,632 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

SEC source: 0001628280-26-013890 · wk-form4_1772573314.xml · derivative · entry 2

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,359

Underlying: Class A Common Stock · 65,359 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

F4 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

SEC source: 0001628280-26-013890 · wk-form4_1772573314.xml · derivative · entry 1

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,359

Underlying: Class A Common Stock · 65,359 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

SEC source: 0001628280-26-013887 · wk-form4_1772573278.xml · derivative · entry 2

Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,622

Underlying: Class A Common Stock · 72,622 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 72,622 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

F4 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 72,622 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

SEC source: 0001628280-26-013887 · wk-form4_1772573278.xml · derivative · entry 1

Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,622

Underlying: Class A Common Stock · 72,622 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

SEC source: 0001628280-26-013882 · wk-form4_1772573232.xml · derivative · entry 2

Daly Jason B. · CIK 0001906486 · EVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,359

Underlying: Class A Common Stock · 65,359 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

F4 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

SEC source: 0001628280-26-013882 · wk-form4_1772573232.xml · derivative · entry 1

Daly Jason B. · CIK 0001906486 · EVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,359

Underlying: Class A Common Stock · 65,359 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

SEC source: 0001628280-26-013878 · wk-form4_1772573190.xml · derivative · entry 2

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,359

Underlying: Class A Common Stock · 65,359 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

F4 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

SEC source: 0001628280-26-013878 · wk-form4_1772573190.xml · derivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,359

Underlying: Class A Common Stock · 65,359 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

SEC source: 0001628280-26-021746 · wk-form4a_1774642844.xml · derivative · entry 1

Patel Chintu · CIK 0001737428 · Director · Co-CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 544,663

Underlying: Class A Common Stock · 544,663 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 544,663 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

F2 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 544,663 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

SEC source: 0001628280-26-021742 · wk-form4a_1774642784.xml · derivative · entry 1

Patel Chirag K. · CIK 0001738701 · Director · President & Co-CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 544,663

Underlying: Class A Common Stock · 544,663 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 544,663 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

F2 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 544,663 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

SEC source: 0001628280-25-053188 · wk-form4_1763587298.xml · nonDerivative · entry 1

Nark Ted C · CIK 0001316851 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 291,029

F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.70 to $11.75 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-25-052413 · wk-form4_1763158428.xml · derivative · entry 5

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 95,525 shares

Expires 2029-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option is fully vested.

SEC source: 0001628280-25-052413 · wk-form4_1763158428.xml · derivative · entry 4

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 36,331 shares

Expires 2028-05-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option is fully vested.

SEC source: 0001628280-25-052413 · wk-form4_1763158428.xml · nonDerivative · entry 3

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,403

F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.85 to $12.02 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-25-052413 · wk-form4_1763158428.xml · nonDerivative · entry 2

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 278,259

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-25-052413 · wk-form4_1763158428.xml · nonDerivative · entry 1

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,734

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001781149-25-000006 · wk-form4_1756412741.xml · nonDerivative · entry 1

Kiely John · CIK 0001781149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,433

F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.20 to $9.25 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001738061-25-000004 · wk-form4_1756153648.xml · nonDerivative · entry 2

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,403

F2 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.50 to $9.51 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001738061-25-000004 · wk-form4_1756153648.xml · nonDerivative · entry 1

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,743

F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.60 to $9.75 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-25-041033 · wk-form4_1755895080.xml · derivative · entry 3

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,480

Underlying: Class A Common Stock · 175,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: These options are fully vested.

F2 · derivative.expiration_date: These options are fully vested.

SEC source: 0001628280-25-041033 · wk-form4_1755895080.xml · nonDerivative · entry 2

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,426

F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.40 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

SEC source: 0001628280-25-041033 · wk-form4_1755895080.xml · nonDerivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 431,670

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001723128-25-000051 · wk-form4_1755289808.xml · nonDerivative · entry 3

Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,152

F3 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.40 to $9.47 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

SEC source: 0001723128-25-000052 · wk-form4_1755289907.xml · nonDerivative · entry 1

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 267,235

F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.16 to $9.41 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001723128-25-000051 · wk-form4_1755289808.xml · nonDerivative · entry 2

Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 341,311

F2 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.34 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

SEC source: 0001723128-25-000051 · wk-form4_1755289808.xml · nonDerivative · entry 1

Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 460,517

F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.12 to $9.40 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

SEC source: 0001723128-25-000050 · wk-form4_1755117633.xml · nonDerivative · entry 1

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 338,929

F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.03 to $9.07 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001723128-25-000049 · wk-form4_1755117561.xml · nonDerivative · entry 1

Daly Jason B. · CIK 0001906486 · EVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,606

F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.01 to $9.13 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.